Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-18

Study Completion Date

2013-05-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study researchers want to learn more about the effectiveness of Iberogast® in patients with irritable stomach and concomitant chronic or recurrent heartburn and backward flow of stomach liquid into the esophagus. 60 patients in the age range from 18 - 80 year will be treated over 4 weeks with Iberogast® or placebo - an inactive substance which looks identical to Iberogast®. Patients completed diaries will provide researchers with detailed information on the change of stomach and intestinal symptoms during the treatment period. In addition information on the acidity of the esophagus and stomach liquid will be collected.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Lidocaine Block on Gastroesophageal Reflux Disease

NCT06304142

Gastroesophageal Reflux Disease

NOT_YET_RECRUITING NA

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

NCT01869491

Gastroesophageal Reflux Disease Dyspepsia

COMPLETED PHASE3

Efficacy and Safety of Itopride vs Placebo in Heartburn

NCT00382577

Heartburn

COMPLETED PHASE3

Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease

NCT00498082

Gastroesophageal Reflux Disease

UNKNOWN

Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux

NCT00414856

Gastroesophageal Reflux Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Functional Gastrointestinal Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

STW5 (Iberogast®, BAY98-7411)

The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.

Group Type EXPERIMENTAL

STW5 (Iberogast®, BAY98-7411)

Intervention Type DRUG

The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.

Placebo

The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

STW5 (Iberogast®, BAY98-7411)

The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.

Intervention Type DRUG

Placebo

The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of either sex aged 18-80 years.
2. Diagnosis of functional dyspepsia according to Rome III criteria:

* Pain or burning localized to the epigastrium of at least moderate severity at least once per week with a total duration of at least 6 months.
* Pain was intermittent.
* Pain was not generalized or localized to other abdominal or chest regions.
* Pain was not relieved by defecation or passage of flatus.
* Pain did not fulfil criteria for gallbladder and sphincter of Oddi disorders.
3. At assessment (visit 1 or 3) three items of GIS had to be judged at least as moderate including reflux symptoms, but reflux symptoms not dominating the clinical picture.
4. Endoscopy of the upper gastrointestinal tract and abdominal sonography without pathological findings that could have explained the symptoms (findings of up to 5 gastric erosions could be tolerated if patient had no concomitant intake of acetylsalicylic acid).
5. Patients willing to comply with the study protocol.
6. Patients who were able to understand and provide written informed consent to participate in the trial (signed informed consent).

Exclusion Criteria

1. Concomitant treatment during the study with any medication that could influence the gastrointestinal function (e.g. prokinetics, antacids, antibiotics, antidepressant, laxatives, calcium antagonists, beta-blocker, antidiarrheics).
2. Regular intake of nonsteroidal antiphlogistic drugs incl. cyclooxygenase-2 (COX-2)-inhibitors (exception: acetylsalicylic acid for cardiovascular prevention up to 100 mg daily).
3. History of clinically relevant gastrointestinal disease such as gastric-, pancreatic-, colon-, rectal-cancer.
4. History of gastric and/or duodenal ulcer.
5. History of abdominal surgery (cholecystectomy and appendectomy could be tolerated).
6. History and/or presence of coronary heart disease.
7. Known intolerance to azo dyes E 110 and E 151.
8. Food allergies and known lactose intolerance.
9. Evidence of any gastrointestinal infectious diseases.
10. Participation in a clinical trial 30 days prior to this trial.
11. Concurrent participation in another clinical trial.
12. Female patients of childbearing potential with a positive pregnancy test, breast feeding, or female patients of childbearing potential without adequate contraception.
13. History and/or presence of drug or alcohol abuse.
14. Patients with psychiatric illness.
15. Irritable bowel syndrome.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No